A new report contains some hopeful news about biphasic mesothelioma survival. Biphasic mesothelioma is the rarest subtype of a rare cancer. It is also the subtype that is hardest to treat. Biphasic mesothelioma survival is typically shorter than other subtypes. But Italian researchers say, with the right combination of mesothelioma treatments, patients with this subtype can achieve long-term survival. Subtypes and their Impact on Biphasic Mesothelioma Survival All pleural mesothelioma tumors grow on the membrane that surrounds the lungs. When this membrane is healthy, it is flexible and expands naturally with each breath. When a mesothelioma tumor grows on this membrane, it can restrict the lungs and make it hard to breathe. As tumors grow, mesothelioma can spread to other … Continue reading Biphasic Mesothelioma Survival Possible in Select Patients
Cancer researchers in New York are exploring the concept of using step counts for cancer prognosis. If further studies back it up, the technique might help predict outcomes for people with mesothelioma. The new study involved people with non-small cell lung cancer. The patients wore commercial fitness trackers so doctors could see how much they walked. The researchers compared step levels with treatment outcomes. They concluded that there is value to using step counts for cancer prognosis. It may even be more effective than some more traditional methods for predicting survival. Cancer Prognosis and Chemoradiotherapy Mesothelioma survival usually depends on how well patients respond to standard treatments. Healthier, more active cancer patients tend to have better outcomes. Chemotherapy and radiation … Continue reading Step Counts for Cancer Prognosis: Could it Work for Mesothelioma?
There is new evidence that adding a drug called vorinostat to immunotherapy might help relapsed pleural mesothelioma patients. The new study comes from the Moffitt Cancer Center in Tampa. It focused on patients with non-small cell lung cancer. Non-small cell lung cancer is similar to pleural mesothelioma in many ways. The study found that patients who received vorinostat along with an immune checkpoint inhibitor had better results. The findings could be good news for relapsed pleural mesothelioma patients, too. Different Immunotherapy Drugs Vorinostat is sold under the brand name Zolinza. It is a histone deacetylase (HDAC) inhibitor. HDAC inhibitors alter the way proteins are expressed inside cells. They also stimulate the immune system. Immune checkpoint inhibitors (ICIs) like Keytruda also … Continue reading New Hope for Relapsed Pleural Mesothelioma?
MD Anderson researchers say too many patients who might benefit from IMRT for mesothelioma never complete the treatment. The problem could be impacting their survival. Intensity Modulated Radiotherapy (IMRT) is a type of targeted radiation. It is designed to direct as much radiation as possible into the mesothelioma tumor without harming the surrounding tissue. Patients who have a combination of surgery, chemotherapy, and IMRT for mesothelioma have the best odds of survival. But at MD Anderson Cancer Center, only two thirds of eligible patients completed IMRT after mesothelioma surgery. The new study aimed to find out why. Trimodal Therapy and Mesothelioma Survival Malignant mesothelioma rarely responds to a single cancer therapy. Trimodal therapy combines several different treatments to maximize success. … Continue reading IMRT for Mesothelioma: Barriers to Completing Treatment
A new kind of mesothelioma treatment called dendritic cell therapy might make other types of treatments even more effective. Right now, chemotherapy with Alimta (pemetrexed) is the only approved therapy for malignant mesothelioma. Many others are in the works. But so far, none of them extend the lives of mesothelioma patients by more than a few months. Dendritic cell therapy for mesothelioma may be different. This novel treatment uses the patient’s own cells to jumpstart the immune system. A Dutch company developed and is testing the new treatment. The data so far suggests that it could boost chemotherapy and help new drugs like Keytruda work better. How Dendritic Cell Therapy Works Dendritic cells are immune system cells that function as … Continue reading Dendritic Cell Therapy for Mesothelioma: Can it Help Other Treatments Work Better?
German doctors testing the HITHOC treatment for pleural mesothelioma say it is a “safe therapeutic option”. The key to success is careful patient selection. Pleural mesothelioma is a rare cancer linked to asbestos. Tumors grow on the membrane that surrounds the lungs. Doctors have not yet found a cure for mesothelioma. HITHOC treatment involves rinsing heated chemotherapy drugs through the chest after mesothelioma surgery. The new study suggests that this advanced approach may help certain mesothelioma patients live longer. Understanding Pleural Mesothelioma Tumors To understand how HITHOC treatment works, it is important to understand how and where mesothelioma tumors grow. Pleural mesothelioma tumors start on the lining around the lungs called the pleura. As tumors grow, the pleura thickens and … Continue reading HITHOC Treatment Deemed Safe for Some Pleural Mesothelioma Patients
Mesothelioma survival rates have stayed steady for decades, even though treatments are improving. According to more than 25 years worth of data from the National Mesothelioma Virtual Bank, people with malignant mesothelioma live a median of 15 months. That number has changed little since 1990. Charting Mesothelioma Patients Over Time Researchers from several major US cancer centers compiled the new report. The goal was to chart mesothelioma survival rates over time and identify factors that impact them. The group evaluated mesothelioma survival rates from 888 cases of pleural and peritoneal mesothelioma in the NMVB. The NMVB houses information on more than 1400 mesothelioma cases diagnosed between 1990 and 2017. Overall mesothelioma survival rates stayed right around 15 months. But there … Continue reading Mesothelioma Survival Rates Have Remained Flat for Decades
The FDA has approved an electricity-based mesothelioma treatment known as Tumor Treating Fields (NovoTTF-100L). The treatment is approved for use along with standard mesothelioma chemotherapy. It is the first new treatment for pleural mesothelioma since the approval of Alimta (pemetrexed) in 2004. Approval of NovoTTF-100L was based on the promising results of the STELLAR phase 2 mesothelioma clinical trial. Those results, released in April, were even better than expected. Electricity is the Basis of Tumor Treating Fields The Tumor Treating Fields approach was created by Jersey-based Novocure. It first found success in the treatment of the deadly brain cancer glioblastoma. The technology uses electrical fields to destabilize critical proteins responsible for cell division. When these proteins cannot do their job, … Continue reading Tumor Treating Fields Win FDA Approval for Mesothelioma Treatment
Pleural and peritoneal mesothelioma rarely occur at the same time. But when they do, there is still hope for treatment. That message comes from a new study conducted at Columbia University and published in the Annals of Surgical Oncology. The researchers analyzed cases of patients diagnosed with both pleural and peritoneal mesothelioma at Columbia. They were looking for the factors that impacted their survival and the most effective ways to treat them. Comparing Pleural and Peritoneal Mesothelioma There are two primary types of malignant mesothelioma, the type of cancer most closely associated with asbestos exposure. The most common type is pleural mesothelioma. With this type, the first tumors show up on the membrane that surrounds the lungs (pleura). Chest pain, … Continue reading When Pleural and Peritoneal Mesothelioma Occur Together
A Japanese study suggests that some mesothelioma doctors are falling short when it comes to communicating with their patients. The study was based on quality-of-life surveys of seventy-three pleural mesothelioma patients. Patients answered two open-ended questions about their care experience. The researchers say most concerns had to do with communication. Many patients said they wanted clearer explanations and more empathy from their mesothelioma doctors. Unique Challenges of Malignant Mesothelioma Coping with any type of cancer can be stressful and confusing. But mesothelioma presents some special challenges to both patients and mesothelioma doctors. Pleural mesothelioma is a rare and complex malignancy with a poor prognosis. No single treatment is likely to help. On top of this, mesothelioma symptoms such as … Continue reading Mesothelioma Doctors Urged to Sharpen Their Communication Skills